Literature DB >> 25118793

Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals.

Robert C Kalayjian1, Kunling Wu, Scott Evans, David B Clifford, Muraldihar Pallaki, Judith S Currier, Marlene Smryzynski.   

Abstract

BACKGROUND: Proteinuria is a marker of vascular dysfunction that predicted increased cardiovascular mortality and is associated with neurocognitive impairment (NCI) in population-based studies. We examined associations between proteinuria and HIV-associated NCI.
METHODS: Multivariable logistic regression was used to examine associations between NCI at the first neurocognitive assessment (baseline) and simultaneous, clinically significant proteinuria [as random spot urine protein-to-creatinine ratios (UP/Cr) ≥200 mg/g] in a prospective multicenter observational cohort study. Generalized estimating equations were used to examine associations between baseline proteinuria and subsequent NCI among subjects without NCI at baseline. NCI was defined as a Z-score, derived from the combination of normalized scores from the Trailmaking A and B and the Wechsler Adult Intelligence Scale-Revised Digit Symbol tests.
RESULTS: A total of 1972 subjects were included in this analysis. Baseline proteinuria was associated with increased odds of NCI [odds ratio (OR): 1.41, 95% confidence interval (CI): 1.08 to 1.85; P = 0.01] and with subsequent NCI among subjects without NCI at baseline (OR: 1.39, 95% CI: 1.01 to 1.93; P = 0.046) in multivariable models adjusted for risk factors and potential confounders. Similar associations were evident when these analyses were limited to visits at which time study subjects maintained plasma HIV RNA levels <200 copies per milliliter.
CONCLUSIONS: The association between proteinuria and NCI observed in this study adds to a growing body of evidence implicating contributions by vascular disease to NCI in antiretroviral treated individuals. Studies examining interventions that improve vascular function are warranted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25118793      PMCID: PMC4133749          DOI: 10.1097/QAI.0000000000000237

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  51 in total

1.  Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study.

Authors:  K Robertson; H Jiang; J Kumwenda; K Supparatpinyo; S Evans; T B Campbell; R Price; S Tripathy; N Kumarasamy; A La Rosa; B Santos; M T Silva; S Montano; C Kanyama; S Faesen; R Murphy; C Hall; C M Marra; C Marcus; B Berzins; R Allen; M Housseinipour; F Amod; I Sanne; J Hakim; A Walawander; A Nair
Journal:  Clin Infect Dis       Date:  2012-06-01       Impact factor: 9.079

2.  Updated research nosology for HIV-associated neurocognitive disorders.

Authors:  A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

3.  Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection.

Authors:  Tricia H Burdo; Allison Weiffenbach; Steven P Woods; Scott Letendre; Ronald J Ellis; Kenneth C Williams
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

4.  Association of cognitive function with albuminuria and eGFR in the general population.

Authors:  Hanneke Joosten; Gerbrand J Izaks; Joris P J Slaets; Paul E de Jong; Sipke T Visser; Henk J G Bilo; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

5.  Cystatin C versus creatinine in determining risk based on kidney function.

Authors:  Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

6.  Plasma apolipoprotein L1 levels do not correlate with CKD.

Authors:  Leslie A Bruggeman; John F O'Toole; Michael D Ross; Sethu M Madhavan; Marlene Smurzynski; Kunling Wu; Ronald J Bosch; Samir Gupta; Martin R Pollak; John R Sedor; Robert C Kalayjian
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

7.  Risk for cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease and greater-than-normal estimated glomerular filtration rate.

Authors:  Jula K Inrig; Barbara S Gillespie; Uptal D Patel; Libbie P Briley; Lilin She; J Donald Easton; Eric Topol; Lynda A Szczech
Journal:  Clin J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 8.237

8.  Small-vessel vascular disease in human immunodeficiency virus infection: the Hawaii aging with HIV cohort study.

Authors:  Aaron McMurtray; Beau Nakamoto; Cecelia Shikuma; Victor Valcour
Journal:  Cerebrovasc Dis       Date:  2007-06-28       Impact factor: 2.762

9.  Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia.

Authors:  Lynn M Wachtman; Richard L Skolasky; Patrick M Tarwater; Deneen Esposito; Giovanni Schifitto; Karen Marder; Michael P McDermott; Bruce A Cohen; Avindra Nath; Ned Sacktor; Leon G Epstein; Joseph L Mankowski; Justin C McArthur
Journal:  Arch Neurol       Date:  2007-09

10.  Age and association of kidney measures with mortality and end-stage renal disease.

Authors:  Stein I Hallan; Kunihiro Matsushita; Yingying Sang; Bakhtawar K Mahmoodi; Corri Black; Areef Ishani; Nanne Kleefstra; David Naimark; Paul Roderick; Marcello Tonelli; Jack F M Wetzels; Brad C Astor; Ron T Gansevoort; Adeera Levin; Chi-Pang Wen; Josef Coresh
Journal:  JAMA       Date:  2012-12-12       Impact factor: 56.272

View more
  1 in total

1.  The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults With Human Immunodeficiency Virus Infection.

Authors:  Kristine M Erlandson; Douglas Kitch; C William Wester; Robert C Kalayjian; Edgar Turner Overton; Jose Castillo-Mancilla; Susan L Koletar; Constance A Benson; Thomas B Campbell; Kevin Robertson; Judith J Lok
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.